Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.

<h4>Background</h4>The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grégoire Mignot, Alice Hervieu, Pierre Vabres, Sophie Dalac, Geraldine Jeudy, Blandine Bel, Lionel Apetoh, François Ghiringhelli
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6081e4e3111d4195adcb82f9d1b529b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6081e4e3111d4195adcb82f9d1b529b5
record_format	dspace
spelling	oai:doaj.org-article:6081e4e3111d4195adcb82f9d1b529b52021-11-25T06:02:32ZProspective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.1932-620310.1371/journal.pone.0105907https://doaj.org/article/6081e4e3111d4195adcb82f9d1b529b52014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25170840/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans.<h4>Methods</h4>In this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests.<h4>Results</h4>We found that chemotherapy induces lymphopenia and that a significantly higher numbers of naïve CD4+ T cells and lower proportion of Treg before chemotherapy are associated with disease control after dacarbazine treatment. Interestingly, NK cell cytotoxicity against dacarbazine-pretreated melanoma cells is only observed in NK cells from patients who achieved disease control.<h4>Conclusion</h4>Together, our data pinpoint that some immune factors could help to predict the response of melanoma patients to dacarbazine. Future larger scale studies are warranted to test their validity as prediction markers.Grégoire MignotAlice HervieuPierre VabresSophie DalacGeraldine JeudyBlandine BelLionel ApetohFrançois GhiringhelliPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e105907 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Grégoire Mignot Alice Hervieu Pierre Vabres Sophie Dalac Geraldine Jeudy Blandine Bel Lionel Apetoh François Ghiringhelli Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
description	<h4>Background</h4>The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans.<h4>Methods</h4>In this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests.<h4>Results</h4>We found that chemotherapy induces lymphopenia and that a significantly higher numbers of naïve CD4+ T cells and lower proportion of Treg before chemotherapy are associated with disease control after dacarbazine treatment. Interestingly, NK cell cytotoxicity against dacarbazine-pretreated melanoma cells is only observed in NK cells from patients who achieved disease control.<h4>Conclusion</h4>Together, our data pinpoint that some immune factors could help to predict the response of melanoma patients to dacarbazine. Future larger scale studies are warranted to test their validity as prediction markers.
format	article
author	Grégoire Mignot Alice Hervieu Pierre Vabres Sophie Dalac Geraldine Jeudy Blandine Bel Lionel Apetoh François Ghiringhelli
author_facet	Grégoire Mignot Alice Hervieu Pierre Vabres Sophie Dalac Geraldine Jeudy Blandine Bel Lionel Apetoh François Ghiringhelli
author_sort	Grégoire Mignot
title	Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
title_short	Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
title_full	Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
title_fullStr	Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
title_full_unstemmed	Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
title_sort	prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/6081e4e3111d4195adcb82f9d1b529b5
work_keys_str_mv	AT gregoiremignot prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT alicehervieu prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT pierrevabres prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT sophiedalac prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT geraldinejeudy prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT blandinebel prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT lionelapetoh prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients AT francoisghiringhelli prospectivestudyoftheevolutionofbloodlymphoidimmuneparametersduringdacarbazinechemotherapyinmetastaticandlocallyadvancedmelanomapatients
_version_	1718414285109985280

Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.

Ejemplares similares